16. Szmaragd C, Wilson AJ, Carpenter S, Wood JL, Mellor PS, et al. (2010) The spread of bluetongue virus serotype 8 in Great Britain and its control by vaccination. PLoS One 5: e9353. 17. De A, Batabyal S, Biswas SK, Chand K, Singh RK, et al. (2009) Surveillance of bluetongue virus antibody in goats using a recombinant VP7-based indirect ELISA in the coastal saline area of West Bengal, India. Vet Ital 45: 339–346. 18. Bhanuprakash V, Indrani BK, Hosamani M, Balamurugan V, Singh RK (2009) Bluetongue vaccines: the past, present and future. Expert Rev Vaccines 8: 191– 204. 19. Wackerlin R, Eschbaumer M, Konig P, Hoffmann B, Beer M (2010) Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle. Vaccine. 20. Dungu B, Potgieter C, Von Teichman B, Smit T (2004) Vaccination in the control of bluetongue in endemic regions: the South African experience. Dev Biol (Basel) 119: 463–472. 21. Santman-Berends IM, Hage JJ, van Rijn PA, Stegeman JA, van Schaik G (2010) Bluetongue virus serotype 8 (BTV-8) infection reduces fertility of Dutch dairy cattle and is vertically transmitted to offspring. Theriogenology 74: 1377–1384. 22. Saegerman C, Mellor P, Uyttenhoef A, Hanon JB, Kirschvink N, et al. (2010) The most likely time and place of introduction of BTV8 into Belgian ruminants. PLoS One 5: e9405. 23. Wilson AJ, Mellor PS (2009) Bluetongue in Europe: past, present and future. Philos Trans R Soc Lond B Biol Sci 364: 2669–2681. 24. Vandenbussche F, De Leeuw I, Vandemeulebroucke E, De Clercq K (2009) Emergence of bluetongue serotypes in Europe, part 1: description and validation of four real-time RT-PCR assays for the serotyping of bluetongue viruses BTV- 1, BTV-6, BTV-8 and BTV-11. Transbound Emerg Dis 56: 346–354. 25. Mehlhorn H, Walldorf V, Klimpel S, Schaub G, Kiel E, et al. (2009) Bluetongue disease in Germany (2007–2008): monitoring of entomological aspects. Parasitol Res 105: 313–319. 26. Mehlhorn H, Walldorf V, Klimpel S, Schmahl G (2008) Outbreak of bluetongue disease (BTD) in Germany and the danger for Europe. Parasitol Res 103 Suppl 1: S79–86. 27. Meiswinkel R, Goffredo M, Dijkstra EG, van der Ven IJ, Baldet T, et al. (2008) Endophily in Culicoides associated with BTV-infected cattle in the province of Limburg, south-eastern Netherlands, 2006. Prev Vet Med 87: 182–195. 28. Toussaint JF, Sailleau C, Breard E, Zientara S, De Clercq K (2007) Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments. J Virol Methods 140: 115–123. 29. Enserink M (2006) Emerging infectious diseases. During a hot summer, bluetongue virus invades northern Europe. Science 313: 1218–1219. 30. Meroc E, Herr C, Verheyden B, Hooyberghs J, Houdart P, et al. (2009) Bluetongue in Belgium: episode II. Transbound Emerg Dis 56: 39–48. 31. Worwa G, Hilbe M, Chaignat V, Hofmann MA, Griot C, et al. (2010) Virological and pathological findings in Bluetongue virus serotype 8 infected sheep. Vet Microbiol. 32. Worwa G, Thur B, Griot C, Hofmann M, MacLachlan JN, et al. (2008) [Bluetongue disease in Swiss sheep breeds: clinical signs after experimental infection with bluetongue virus serotype 8]. Schweiz Arch Tierheilkd 150: 491– 498. 33. Jonsson CB, White EL (2007) Launching an HTS campaign to discover new antivirals. European Pharmaceutical Review: 4. 34. Li Q, Maddox C, Rasmussen L, Hobrath JV, White LE (2009) Assay development and high-throughput antiviral drug screening against Bluetongue virus. Antiviral Res 83: 267–273. 35. Phillips T, Jenkinson L, McCrae C, Thong B, Unitt J (2011) Development of a high-throughput human rhinovirus infectivity cell-based assay for identifying antiviral compounds. J Virol Methods 173: 182–188. 36. Noah JW, Severson W, Noah DL, Rasmussen L, White EL, et al. (2007) A cell- based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res 73: 50–59. 37. Mortola E, Larsen A (2009) [Bluetongue virus infection: signaling pathway activated during apoptosis]. Rev Argent Microbiol 41: 134–140. 38. Stauber N, Martinez-Costas J, Sutton G, Monastyrskaya K, Roy P (1997) Bluetongue virus VP6 protein binds ATP and exhibits an RNA-dependent ATPase function and a helicase activity that catalyze the unwinding of double- stranded RNA substrates. J Virol 71: 7220–7226. 39. Cherra SJ, 3rd, Dagda RK, Chu CT (2010) Review: autophagy and neurodegeneration: survival at a cost? Neuropathol Appl Neurobiol 36: 125– 132. 40. Singletary K, Milner J (2008) Diet, autophagy, and cancer: a review. Cancer Epidemiol Biomarkers Prev 17: 1596–1610. 41. Larsen KE, Sulzer D (2002) Autophagy in neurons: a review. Histol Histopathol 17: 897–908. 42. Wileman T (2006) Aggresomes and autophagy generate sites for virus replication. Science 312: 875–878. 43. Law AH, Lee DC, Yuen KY, Peiris M, Lau AS (2010) Cellular response to influenza virus infection: a potential role for autophagy in CXCL10 and interferon-alpha induction. Cell Mol Immunol 7: 263–270. 44. Rossman JS, Lamb RA (2009) Autophagy, apoptosis, and the influenza virus M2 protein. Cell Host Microbe 6: 299–300. 45. Zhou Z, Jiang X, Liu D, Fan Z, Hu X, et al. (2009) Autophagy is involved in influenza A virus replication. Autophagy 5: 321–328. Virostatic Agents against Bluetongue Virus 46. Dreux M, Chisari FV (2009) Autophagy proteins promote hepatitis C virus replication. Autophagy 5: 1224–1225. 47. Dreux M, Gastaminza P, Wieland SF, Chisari FV (2009) The autophagy machinery is required to initiate hepatitis C virus replication. Proc Natl Acad Sci U S A 106: 14046–14051. 48. Heaton NS, Randall G (2010) Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe 8: 422–432. 49. Bartram DJ, Heasman L, Batten CA, Oura CA, Plana-Duran J, et al. (2011) Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines. Vet J. 50. Hamers C, Galleau S, Chery R, Blanchet M, Besancon L, et al. (2009) Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle. Vet Rec 165: 369–373. 51. Pubchem Bioassay. MLS000673879 - Substance Summary (SID 24798053). h t t p : / / p u b c h e m . n c b i . n l m . n i h . g o v / s u m m a r y / s u m m a r y . cgi?sid = 24798053&loc = es_rss. 52. Clarke TE, Clem RJ (2003) Insect defenses against virus infection: the role of apoptosis. Int Rev Immunol 22: 401–424. 53. Everett H, McFadden G (1999) Apoptosis: an innate immune response to virus infection. Trends Microbiol 7: 160–165. 54. Koyama AH, Irie H, Fukumori T, Hata S, Iida S, et al. (1998) Role of virus- induced apoptosis in a host defense mechanism against virus infection. J Med Invest 45: 37–45. 55. Stewart ME, Roy P (2010) Role of cellular caspases, nuclear factor-kappa B and interferon regulatory factors in Bluetongue virus infection and cell fate. Virol J 7: 362. 56. Mortola E, Noad R, Roy P (2004) Bluetongue virus outer capsid proteins are sufficient to trigger apoptosis in mammalian cells. J Virol 78: 2875–2883. 57. Nagaleekar VK, Tiwari AK, Kataria RS, Bais MV, Ravindra PV, et al. (2007) Bluetongue virus induces apoptosis in cultured mammalian cells by both caspase-dependent extrinsic and intrinsic apoptotic pathways. Arch Virol 152: 1751–1756. 58. Yorimitsu T, Klionsky DJ (2005) Autophagy: molecular machinery for self- eating. Cell Death Differ 12 Suppl 2: 1542–1552. 59. Fimia GM, Piacentini M (2009) Toward the understanding of autophagy regulation and its interplay with cell death pathways. Cell Death Differ 16: 933– 934. 60. Gougeon ML, Piacentini M (2009) New insights on the role of apoptosis and autophagy in HIV pathogenesis. Apoptosis 14: 501–508. 61. Dreux M, Chisari FV Viruses and the autophagy machinery. Cell Cycle 9: 1295–1307. 62. Orvedahl A, Levine B (2009) Eating the enemy within: autophagy in infectious diseases. Cell Death Differ 16: 57–69. 63. Lee YR, Lei HY, Liu MT, Wang JR, Chen SH, et al. (2008) Autophagic machinery activated by dengue virus enhances virus replication. Virology 374: 240–248. 64. Khakpoor A, Panyasrivanit M, Wikan N, Smith DR (2009) A role for autophagolysosomes in dengue virus 3 production in HepG2 cells. J Gen Virol 90: 1093–1103. 65. Panyasrivanit M, Khakpoor A, Wikan N, Smith DR (2009) Co-localization of constituents of the dengue virus translation and replication machinery with amphisomes. J Gen Virol 90: 448–456. 66. Jackson WT, Giddings TH, Jr., Taylor MP, Mulinyawe S, Rabinovitch M, et al. (2005) Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol 3: e156. 67. Prentice E, Jerome WG, Yoshimori T, Mizushima N, Denison MR (2004) Coronavirus replication complex formation utilizes components of cellular autophagy. J Biol Chem 279: 10136–10141. 68. Hyser JM, Utama B, Crawford SE, Estes MK Genetic divergence of rotavirus nonstructural protein 4 results in distinct serogroup-specific viroporin activity and intracellular punctate structure morphologies. J Virol 86: 4921–4934. 69. Berkova Z, Crawford SE, Trugnan G, Yoshimori T, Morris AP, et al. (2006) Rotavirus NSP4 induces a novel vesicular compartment regulated by calcium and associated with viroplasms. J Virol 80: 6061–6071. 70. Roy P, Noad R (2006) Bluetongue virus assembly and morphogenesis. Curr Top Microbiol Immunol 309: 87–116. 71. Celma CC, Roy P (2009) A viral nonstructural protein regulates bluetongue virus trafficking and release. J Virol 83: 6806–6816. 72. Harty RN (2009) No exit: targeting the budding process to inhibit filovirus replication. Antiviral Res 81: 189–197. 73. Buchholz UJ, Finke S, Conzelmann KK (1999) Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73: 251–259. 74. Mertens PP, Burroughs JN, Anderson J (1987) Purification and properties of virus particles, infectious subviral particles, and cores of bluetongue virus serotypes 1 and 4. Virology 157: 375–386. 75. Kar AK, Roy P (2003) Defining the structure-function relationships of bluetongue virus helicase protein VP6. J Virol 77: 11347–11356. 76. Landry ML, Stanat S, Biron K, Brambilla D, Britt W, et al. (2000) A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 44: 688–692. PLOS ONE | www.plosone.org 11 August 2012 | Volume 7 | Issue 8 | e43341